Drug Trial Radar · NCT02437318
Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.
Last checked: Nov 20, 2026Latest source record: Feb 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
572
Actual
Start
Jul 23, 2015
Primary completion
Jun 12, 2018
Study completion Jun 9, 2023
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- May 7, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To determine whether treatment with alpelisib plus fulvestrant prolonged progression-free survival (PFS) compared to fulvestrant and placebo in men and postmenopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor-2 (HER2)-negative advanced breast cancer, who received prior treatment with an aromatase Inhibitor (AI) either as (neo)adjuvant or for advanced disease.
Conditions
- Breast Cancer
Interventions
FulvestrantDrug
500 mg of fulvestrant administered via intramuscular injection on Day 1 and Day 15 of Cycle 1, and then Day 1 of each subsequent 28-day cycle
AlpelisibDrug
300 mg of alpelisib tablets for oral use administered once daily
PlaceboDrug
300 mg of placebo tablets for oral use administered once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival (PFS) Per Investigator Assessment in the PIK3CA Mutant CohortTime frame: Once approximately 243 PFS events in the PIK3CA mutant cohort had been observed, up to 33.3 months
Locations
197 sites in 31 countries. Site status is shown where the registry gives one.
Ironwood Cancer and Research Centers
Chandler, Arizona
Mayo Clinic Arizona
Scottsdale, Arizona
Highlands Oncology Group
Fayetteville, Arkansas
Beverly Hills Cancer Center
Beverly Hills, California
City of Hope National Medical Center
Duarte, California
Scripps Green Hospital
La Jolla, California
Kaiser Permanent Southern Californi
San Diego, California
UCSF
San Francisco, California
Florida Cancer Specialists
Fort Myers, Florida
Florida Cancer Specialists-North
St. Petersburg, Florida
Rush University Medical Center
Chicago, Illinois
NorthShore University Health System
Evanston, Illinois
Edward Cancer Center
Naperville, Illinois
Fort Wayne Medical Oncology Hematology Inc
Fort Wayne, Indiana
St Francis Health Comprehensive Cancer Center
Topeka, Kansas
Mercy Medical Center
Baltimore, Maryland
Massachusetts General Hospital
Boston, Massachusetts
Lahey Clinic
Burlington, Massachusetts
Detroit Clinical Research Center
Owosso, Michigan
St Lukes Cancer Institute
Kansas City, Missouri
St Vincent Frontier Cancer Center
Billings, Montana
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey
University Hospitals of Cleveland Seidman Cancer Center
Cleveland, Ohio
Good Samaritan Regional Medical Center
Corvallis, Oregon
Lancaster General Hospital
Lancaster, Pennsylvania
Prisma Health Upstate
Greenville, South Carolina
Avera Cancer
Sioux Falls, South Dakota
SCRI Oncology Partners
Nashville, Tennessee
Texas Oncology PA Dallas Presbyterian Hospital
Dallas, Texas
El Paso Texas Oncology
El Paso, Texas
Mays Cancer Ctr Uthsa Mdacc
San Antonio, Texas
Texas Oncology Northeast Texas
Tyler, Texas
Virginia Cancer Specialists
Fairfax, Virginia
Wenatchee Valley Medical Center
Wenatchee, Washington
Novartis Investigative Site
La Rioja, Argentina
Novartis Investigative Site
Berazategui, Buenos Aires, Argentina
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Novartis Investigative Site
Rio Negro, Viedma, Argentina
Novartis Investigative Site
Wahroonga, New South Wales, Australia
Novartis Investigative Site
Wooloongabba, Queensland, Australia
Showing 40 of 197 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.